Cellectis S.A.
CLLS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.07 | -0.04 | -0.25 |
| FCF Yield | 11.98% | -14.70% | -93.96% | -33.83% |
| EV / EBITDA | -11.76 | -1.34 | -1.07 | -3.56 |
| Quality | ||||
| ROIC | -25.84% | -50.63% | -42.52% | -30.14% |
| Gross Margin | 77.88% | -882.65% | 55.75% | 93.92% |
| Cash Conversion Ratio | -0.60 | 0.21 | 0.89 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.37% | -70.81% | -27.86% | 25.95% |
| Free Cash Flow Growth | 175.62% | 71.28% | 26.99% | 1.26% |
| Safety | ||||
| Net Debt / EBITDA | 5.47 | 0.56 | 0.18 | 1.08 |
| Interest Coverage | -7.99 | -18.33 | -23.68 | -23.69 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -539.34 | 10,243.90 | -588.49 | -4,329.69 |